Introduction: Cholestasis is a liver disease caused by a malfunction of the hepato-biliary system. Oxidative stress as a systemic complication is the main characteristic of cholestasis. The aim of this study was to evaluate the antiinflammatory and hepatoprotective effects of Portulaca oleracea (PO) methanolic extract on liver dysfunction and tissue damage induced by bile duct ligation (BDL) in rats. Materials and methods: Twenty-eight male Wistar rats were randomly divided into four groups: sham control (SC), BDL alone, SC plus 500 mg/kg methanolic extract of PO orally for 1 week, and BDL plus 500 mg/kg methanolic extract of PO orally for 1 week. After 1 week, the animals were anesthetized, and the liver and blood samples were taken from each animal. Biochemical parameters, oxidative stress biomarkers, histopathological changes, as well as the gene expression of IL-1, TNF-α, TGF-β, and α-SMA have been evaluated. Results:The methanolic extract of PO at a dose of 500 mg/kg significantly decreased the plasma levels of aminotransferases, alkaline phosphatase as compared to BDL group (P < 0.05), while it had no significant effect on the levels of oxidative stress markers in the hepatic tissue. The plasma level of malondialdehyde and ferricreducing antioxidant power were markedly elevated in the BDL group in comparison to SC group (P < 0.05), while treatment with PO significantly reduced these markers (P < 0.05). The administration of PO attenuated hydroxyproline content, bile duct proliferation, and inflammation score in the cholestatic liver in contrast to nontreated BDL rats (P < 0.05). Moreover, the methanolic extract of PO markedly declined the expression of TNF-α and TGF-β pro inflammatory genes in contrast to BDL rats. Conclusions: Taken together, our findings showed that PO attenuated liver injury by decreasing liver function tests, inflammation, and hydroxyproline content. As a result, it is suggested that PO can be applied in cholestatic liver damage as a therapeutic or adjuvant agent.

No abstract

Purpose Metabolic syndrome contains metabolic disorders that have association with other chronic diseases. Melatonin is a bioactive compound which is found in plants and also produced in the body. The purpose of this paper is to assess the effect of melatonin supplement on metabolic syndrome components, also leptin and adiponectin blood concentrations in patients with metabolic syndrome. Design/methodology/approach A double blind, placebo-controlled, randomized clinical trial was conducted on 70 subjects with metabolic syndrome. Participants received 6 mg/day melatonin or placebo before bedtime for 12 weeks. At the beginning and end of treatment period, blood samples were collected and biochemical parameters were measured. In addition, blood pressure and anthropometric indices were examined before and after the supplementation. Independent sample t-test was used to compare changes in metabolic syndrome components between the two study groups. Findings Results showed a significant reduction in waist circumference (−1.54 vs −0.04 cm; p = 0.036), systolic blood pressure (−3.52 vs 0.79 mmHg; p = 0.020), diastolic blood pressure (−1.50 vs 1.73 mmHg; p = 0.014), serum leptin concentration (−2.54 vs 0.27ng/ml; p = 0.041) and an elevation in high-density lipoprotein cholesterol (2.19 vs −0.79 mg/dl; p = 0.038) in the melatonin group compared to the placebo. Research limitations/implications If insulin concentration had been measured, it might have revealed better interpretation of melatonin effect on fasting blood glucose. Originality/value This study showed that melatonin as a nutritional supplement improved most metabolic syndrome components and concentration of leptin in the melatonin group compared to the placebo.

No abstract

In the present study, magnesium oxide/granular activated carbon (MgO/GAC) composite as a catalyst was synthesized using the sol-gel method and its catalytic potential was investigated in the presence of ultraviolet (UV) irradiation for the removal of cephalexin (CLX) in a batch mode reactor. Then, the characterization of the MgO/GAC composite was determined by X-ray diffraction (XRD) and scanning electron microscopy (SEM). Next, the effect of operational parameters was evaluated, including the pH of the solution (3-11), the dosage of composite (1-6 g/L), initial CLX concentration (20-100 mg/L), and contact time (10-60 minutes). The maximum CLX degradation with an initial concentration of 20 mg/L was as high as 98% at pH=3, 4 g/L of MgO/GAC composite with UV irradiation within 60-minute contact time. In addition, the removal process of CLX could be described by the pseudofirst-order kinetic. Further, the chemical oxygen demand (COD) and total organic carbon (TOC) removal rate were 78% and, 62.3% in optimum conditions, respectively. The results indicated that the UV/MgO/GAC hybrid photocatalytic process can be considered as an efficient alternative for treating the wastewater containing CLX.

No abstract